Evidence map›Paper›PMID 21367971›Full record

ArticleRNA (New York, N.Y.)2011

An expanded collection and refined consensus model of glmS ribozymes.

Phillip J McCown, Adam Roth, Ronald R Breaker

Open access · bronzeAbstract read
In one paragraph

Article in RNA (New York, N.Y.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The current riboswitch landscape inMicrobiology (Reading, England) · 2024
    Review
  5. Article
  6. Article
  7. Discovering riboswitches: the past and the future.Trends in biochemical sciences · 2023
    Review
  8. Article
  9. Article
  10. A Riboswitch-Driven Era of New Antibacterials.Antibiotics (Basel, Switzerland) · 2022
    Review
  11. The case of the missing allosteric ribozymes.Nature chemical biology · 2021
    Review
  12. Riboswitches as Drug Targets for Antibiotics.Antibiotics (Basel, Switzerland) · 2021
    Review
  13. Article
  14. Article
  15. Riboswitch diversity and distribution.RNA (New York, N.Y.) · 2017
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Phillip J McCownDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520-8103, USA.
Adam Roth
Ronald R Breaker
Howard Hughes Medical Institute · USYale University · US

Funding

X-RAY ANALYSIS OF PROTEIN STRUCTURE AND FUNCTIONP01GM022778 · NIGMS · YALE UNIVERSITY · PI BREAKER, RONALD R · 1985 to 2019
$26.1M
PREDOCTORAL TRAINING PROGRAM IN GENETICST32GM007499 · NIGMS · YALE UNIVERSITY · PI CARLSON, JOHN R, REINKE, VALERIE J · 1985 to 2022
$13.9M
YALE BIOMEDICAL SUPERCOMPUTER: NEUROSCIENCES10RR019895 · NCRR · YALE UNIVERSITY · PI WILLIAMS, KENNETH ROBERT · 2004 to 2004
$1.6M
Howard Hughes Medical InstituteNCRR NIH HHS RR19895-02NCRR NIH HHS S10 RR019895NIGMS NIH HHS P01 GM022778NIGMS NIH HHS P01 GM022778-34NIGMS NIH HHS T32 GM007499NIGMS NIH HHS T32GM007499
6 · The paper itself

Abstract

Self-cleaving glmS ribozymes selectively bind glucosamine-6-phosphate (GlcN6P) and use this metabolite as a cofactor to promote self-cleavage by internal phosphoester transfer. Representatives of the glmS ribozyme class are found in Gram-positive bacteria where they reside in the 5' untranslated regions (UTRs) of glmS messenger RNAs that code for the essential enzyme L-glutamine:D-fructose-6-phosphate aminotransferase. By using comparative sequence analyses, we have expanded the number of glmS ribozyme representatives from 160 to 463. All but two glmS ribozymes are present in glmS mRNAs and most exhibit striking uniformity in sequence and structure, which are features that make representatives attractive targets for antibacterial drug development. However, our discovery of rare variants broadens the consensus sequence and structure model. For example, in the Deinococcus-Thermus phylum, several structural variants exist that carry additional stems within the catalytic core and changes to the architecture of core-supporting substructures. These findings reveal that glmS ribozymes have a broader phylogenetic distribution than previously known and suggest that additional rare structural variants may remain to be discovered.

Indexed as

Conserved SequenceRiboswitchBase SequenceDeinococcusGlucosamineGlucose-6-PhosphateModels, MolecularMolecular Sequence DataNucleic Acid ConformationRNA, CatalyticThermusGlucosamineglucosamine 6-phosphateGlucose-6-PhosphateRiboswitchRNA, Catalytic

Identifiers

PMID21367971
PMCPMC3062183
OpenAlexW2124594883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.